Author: Benzinga Newsdesk | August 12, 2025 07:38am
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 20.69 percent. This is a 40 percent decrease over losses of $(0.05) per share from the same period last year.